Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Top Biotech stocks for cancer cures from Cowen

16/05/2014 by

W1siziisijiwmtqvmtavmjgvmtuvndivmdgvotk2l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

The conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance at the American Society of Clinical Oncology yearly conference. Many of the top names present key data sets at their presentations, with some being brand new and some updating previously released results. With cancer expected to be the leading cause of death within the next 20 years, the top biotech companies are focusing on new treatments that may provide incredible breakthroughs.

The biotech team at Cowen has done a summary of data released or that will be released from some of the top biotech names in their coverage universe. Here is some of the commentary on stocks the firm rates as Outperform.

Amgen Inc, is the top blue chip name in the biotech world and at Cowen. A biotechnology pioneer since 1980, Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people‚Äôs lives. The company trades at a low 12.6 times forward earnings. The company will present for the first time results from its potentially pivotal Phase 2 trial of blinatumomab, which is a bi-specific T-cell engaging antibody that targets CD3+ T-cells to cancer cells expressing a tumor specific antigen. The biotech giant pays investors a solid 2.2% dividend. The Thomson/First Call price target for the stock is $132.64. Amgen closed Thursday at $110.29 a share.

This article has been extracted from http://247wallst.com, please click on this link to read the article in full http://247wallst.com/healthcare-business/2014/05/16/top-biotech-stocks-for-cancer-cures-from-cowen/

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

For more information please visit www.montash.com

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdkvmjkvmdgvmtmvmjkvmjgyl1vudgl0bgvkigrlc2lnbiaomjuplmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Are PSLs a Blocker or an Enabler?

2017-10-02 11:00:00 +0100

The use of a Preferred Supplier List (PSL) was intended to support and strengthen relationships and performance between organisations and their third party suppliers. As the technical landscape continues to evolve at rapid rate recruitment and demand for new skills becomes more intense. Are PSLs still the solution or an obstacle to sourcing the right talent? The traditional PSL A dedicated list of partners intended to guarantee quality and availability ...

W1siziisijiwmtcvmdkvmjevmdgvndmvmduvmtmxl1vudgl0bgvkigrlc2lnbiaomjmplmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Why do we punish the victims of hacking?

2017-09-21 09:00:00 +0100

Hacks occur every 39 seconds, with 95% of them targeting governments, retailers and the tech industry. If the hackers are caught, they'll face prison time under the Computer Misuse Act. More often than not, the businesses who are victims of those attacks expose themselves to punishment of their own. The laws that determine the duty of protection owed to businesses and their customers is both vague and broad, making them question just how much protection...